{
    "clinical_study": {
        "@rank": "4671", 
        "arm_group": [
            {
                "arm_group_label": "Synera", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Inactive Patch", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "Knee osteoarthritis (OA) can result in significant pain and limitation of function.  A\n      number of topical non-steroidal anti-inflammatory drugs have been shown to reduce pain in\n      this condition.  This study examines a different topical approach, utilizing a topical\n      anesthetic agent, to evaluate if application of such an agent would provide relief of\n      exercise-induced knee pain in people with knee OA."
        }, 
        "brief_title": "Efficacy and Safety of Synera in Osteoarthritis Pain", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Knee Osteoarthritis", 
        "condition_browse": {
            "mesh_term": [
                "Osteoarthritis", 
                "Osteoarthritis, Knee"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Men and women, age 40 years and above\n\n          2. Meet American College of Rheumatology criteria for knee OA\n\n          3. Knee pain most days of the week for the past month\n\n          4. Knee pain > 5/10 after exercise intervention\n\n          5. Capable of undertaking exercise intervention\n\n          6. Stable cardiovascular function\n\n          7. Able to return for all clinic visits\n\n          8. Able to read and understand the informed consent document\n\n        Exclusion Criteria:\n\n          1. Use of a walker to ambulate or inability to ambulate\n\n          2. Other forms of arthritis\n\n          3. Other major causes of pain that could be expected to interfere with assessment of\n             pain during this trial, e.g., recurrent migraine, back pain, fibromyalgia\n\n          4. History of myocardial infarction\n\n          5. Blood Pressure > 140 systolic/100 diastolic\n\n          6. Scheduled for and likely to need joint replacement surgery in the next 3 months\n\n          7. Any medical condition that in the judgment of the investigator would make the\n             participant not suitable for the study\n\n          8. Sensitivity to lidocaine, topical or injectable analgesics/anesthetics."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 11, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01654302", 
            "org_study_id": "STU00061115"
        }, 
        "intervention": [
            {
                "arm_group_label": "Synera", 
                "description": "70 mg lidocaine/ 70 mg tetracaine topical patch applied once for 12 hours", 
                "intervention_name": "70 mg lidocaine/ 70 mg tetracaine topical patch", 
                "intervention_type": "Drug", 
                "other_name": "Synera"
            }, 
            {
                "arm_group_label": "Inactive Patch", 
                "description": "placebo", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Tetracaine", 
                "Lidocaine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 18, 2014", 
        "location": {
            "contact": {
                "email": "julia.marks@northwestern.edu", 
                "last_name": "Julia Marks", 
                "phone": "312-503-1215"
            }, 
            "facility": {
                "address": {
                    "city": "Chicago", 
                    "country": "United States", 
                    "state": "Illinois", 
                    "zip": "60611"
                }, 
                "name": "Northwestern University"
            }, 
            "investigator": {
                "last_name": "Thomas J Schnitzer, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy and Safety of Synera in OA Pain", 
        "overall_contact": {
            "email": "julia.marks@northwestern.edu", 
            "last_name": "Julia Marks", 
            "phone": "312-503-1215"
        }, 
        "overall_official": {
            "affiliation": "Northwestern University", 
            "last_name": "Thomas J Schnitzer, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "knee pain scores on a numeric rating scale (NRS)", 
            "safety_issue": "No", 
            "time_frame": "during the 5 minutes after exercise"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01654302"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Northwestern University", 
            "investigator_full_name": "Thomas J. Schnitzer", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "composite arthritis score on the Western Ontario and McMaster Universities Arthritis Index (WOMAC)", 
                "safety_issue": "No", 
                "time_frame": "1 and 5 minutes, 12 hours and 1 day after exercise"
            }, 
            {
                "measure": "Quality of life on the Short Form 12 (SF12)", 
                "safety_issue": "No", 
                "time_frame": "1 and 5 minutes, 12 hours and 1 day after exercise"
            }, 
            {
                "measure": "pain quality on the Pain Quality Assessment Scale (PQAS)", 
                "safety_issue": "No", 
                "time_frame": "1 and 5 minutes, 12 hours and 1 day after exercise"
            }
        ], 
        "source": "Northwestern University", 
        "sponsors": {
            "collaborator": {
                "agency": "Nuvo Research Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Thomas J. Schnitzer", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}